Open Access Open Badges Research

Isoforms of Retinol binding protein 4 (RBP4) are increased in chronic diseases of the kidney but not of the liver

Simone K Frey1*, Britta Nagl1, Andrea Henze1, Jens Raila1, Beate Schlosser2, Thomas Berg2, Martin Tepel3, Walter Zidek3, Martin O Weickert45, Andreas FH Pfeiffer45 and Florian J Schweigert1

Author Affiliations

1 Institute of Nutritional Science, University of Potsdam, Potsdam-Rehbrücke, Germany

2 Medical Department, Devision of Hepatology and Gastroenterolgy, Campus Virchow-Clinic, Charité, University Medicine, Berlin

3 Department of Medicine IV, Charité Campus Benjamin Franklin, Berlin, Germany

4 Department of Clinical Nutrition, German Institute of Human Nutrition, Potsdam-Rehbrücke, Germany

5 Department of Endocrinology, Diabetes and Nutrition, Charité University Medicine, Berlin, Germany

For all author emails, please log on.

Lipids in Health and Disease 2008, 7:29  doi:10.1186/1476-511X-7-29

Published: 27 August 2008



The levels of retinol-binding protein 4 (RBP4) – the carrier protein for Vitamin A in plasma – are tightly regulated under healthy circumstances. The kidney, the main site of RBP4 catabolism, contributes to an elevation of RBP4 levels during chronic kidney disease (CKD) whereas during chronic liver disease (CLD) RBP4 levels decrease. Little is known about RBP4 isoforms including apo-RBP4, holo-RBP4 as well as RBP4 truncated at the C-terminus (RBP4-L and RBP4-LL) except that RBP4 isoforms have been reported to be increased in hemodialysis patients. Since it is not known whether CLD influence RBP4 isoforms, we investigated RBP4 levels, apo- and holo-RBP4 as well as RBP4-L and RBP4-LL in plasma of 36 patients suffering from CKD, in 55 CLD patients and in 50 control subjects. RBP4 was determined by ELISA and apo- and holo-RBP4 by native polyacrylamide gel electrophoresis (PAGE). RBP4-L and RBP4-LL were analyzed after immunoprecipitation by mass spectrometry (MALDI-TOF-MS).


RBP4 isoforms and levels were highly increased in CKD patients compared to controls (P < 0.05) whereas in CLD patients RBP4 isoforms were not different from controls. In addition, in hepatic dysfunction RBP4 levels were decreased whereas the amount of isoforms was not affected.


The occurrence of RBP4 isoforms is not influenced by liver function but seems to be strongly related to kidney function and may therefore be important in investigating kidney function and related disorders.